challenges
CAR-T cell therapy has been a game changer for blood-based cancers, providing a curative, single-treatment option for the first time in history. Existing treatments for solid tumours have mixed efficacy, so the holy grail is making CAR-T therapy work for solid tumours.
solution
Currus have developed a platform technology that enables any CAR-T therapy to be presented to the immune system such that it will persist and expand in vivo, enabling for the first time, the therapy to infiltrate the hostile solid tumour microenvironment and clear the tumour.
You might also like
For founders
Building for the systems that matter? Pitch us.
We back founders turning breakthrough science into category-defining companies.
For investors
Invest with Main Sequence
Access Australia's deep tech frontier alongside us.







